A study analyzing efficacy of early treatment versus low efficacy early treatment paradigms on serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) outcomes
Latest Information Update: 20 Aug 2022
At a glance
- Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Glatiramer acetate (Primary) ; Natalizumab (Primary) ; Ocrelizumab (Primary) ; Rituximab (Primary) ; Teriflunomide (Primary) ; Interferons
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Acronyms CLIMB
Most Recent Events
- 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology
- 02 Jun 2022 New trial record
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022